Google+

Bad News for Alzheimer’s Sufferers

Biogen has abandoned late-stage clinical trials for a previously promising Alzheimer's drug
Biogen has abandoned late-stage clinical trials for a previously promising Alzheimer’s drug(Credit: AndrewLozovyi/Depositphotos)

A shockwave reverberated through the Alzheimer’s research community today after pharmaceutical company Biogen announced it was discontinuing two massive final phase human trials into the previously promising Alzheimer’s drug aducanumab. The announcement is the latest in a long line of failed Alzheimer’s drugs targeting the popular amyloid protein hypothesis. read more